|
Torrent Pharmaceuticals (Emkay) Torrent Pharma |
|
Result Highlights;Future growth drivers | Date | Rating | Target Price | Recommendation Price | Broker house | | 4 Aug 2011 | hold | 663 (from 598) | 641 | Emkay Report | |
|
Torrent Pharmaceuticals (ICICI securities) Still scope for improvement |
|
Domestic business witnesses marginal YoY growth;Launches two products in US market | Date | Rating | Target Price | Recommendation Price | Broker house | | 3 Aug 2011 | hold | 678 (from 657) | 646 | ICICI securities Report | |
|
Torrent Pharmaceuticals (HSBC) Where mid-caps have an edge |
|
Mid-caps thrive on Indian domestic growth and emerging markets | Date | Rating | Target Price | Recommendation Price | Broker house | | 17 Jun 2011 | neutral;(Initiation) | 715 | -- | HSBC Report | |
|
Torrent Pharma (ICICIsecurities) Weak quarter |
|
Expanding footprints; Total revenues grow 16% YoY in FY 11 |
|
torrent pharma (Emkay) Margin pressure to continue; Downgrade estimates |
|
Q4’11 was impacted by write-off in the US market and delayed shipment to Brazil. Revenues at Rs5.1bn, (up 8% YoY), EBITDA at Rs536mn (down 45%) & PAT at Rs428mn (down 28% YoY)
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 1 Jun 2011 |
buy (from hold) |
598 |
619 |
Emkay Report |
|
|
Torrent Pharma (Edelweiss) Strong play on branded generics |
|
Mid Caps - Seize the moment;Strong play on branded generics; Consolidation phase from investments in domestic and international markets is largely over with potential margin expansion over FY12-13E | Date | Rating | Target Price | Recommendation Price | Broker house | | 24 May 2011 | buy | 760 | 630 | Edelweiss Report | |
|
torrent pharmaceuticals (ICICIsec) Chronic focus, generics to drive growth |
|
torrent pharma (Emkay) In-line Results; Maintain Buy |
|
torrent pharmaceuticals (ICICIsec) Chronic focus, generics to drive growth |
|
Torrent Pharma (Emkay) On Track; Maintain Buy |
| Date |
Rating |
Target Price |
Recommendation Price |
Broker house |
| 25 Oct 2010 |
Buy |
650 |
558 |
Emkay report |
Reports.DesiStockResearch.com |
